等待開盤 05-20 09:30:00 美东时间
-0.085
-2.73%
Key highlights from the first quarter of operations under the expanded management team include the following:Anticipated FDA decision on the Company's ANDA for Preservative-Free Ketamine in Q3 2026, with favorable
05-18 19:12
NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.04) per share. This is a 88.24 percent increase over losses of $(0.34) per share from the same period last year. The company reported $1.068 million in
05-16 05:55
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a biopharmaceutical company that focuses on neuroplastic therapies for depression, PTSD, and related conditions, today announces initiation of a first commercial manufacturing
05-05 19:13
今日重点评级关注:Ascendiant Capital:维持NRX Pharmaceuticals"买入"评级,目标价从48美元升至49美元;Chardan Capital:维持Intellia Therapeutics"买入"评级,目标价从27美元升至30美元
04-28 10:07
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $45 price target.
04-27 19:07
特朗普签署行政令加速PTSD疗法研发!迷幻药物板块集体飙升,CMPS涨42%;国防科技IPO热度持续升温!军用无人机制造商Aevex上市两日股价涨近70%>>
04-21 15:31
In the Order, the President notes that, "It is the policy of my Administration to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs that could save lives and
04-20 19:02
NRx has received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for NRx's preservative-free ketamine product. Labeling remains subject to final supervisory review.NRx
04-06 19:05
今日重点评级关注:Guggenheim:维持Cabaletta Bio"买入"评级,目标价从15美元升至16美元;HC Wainwright & Co.:维持Palvella Therapeutics"买入"评级,目标价从255美元升至270美元
03-25 10:31
BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $25 price target.
03-25 00:27